Every Breakthrough Starts With A Blueprint
Leveraging Years of Experience and Deep Pharmacological Insight to Drive Your Drug Discovery Success
How We Can Help
Therapeutic Development
Expertise in advancing therapeutic candidates from preclinical research to Phase III clinical trials.
Biologics Drug Discovery
Expertise in creating first- and best-in-class therapeutics for all modalities of biologics.
Regulatory Strategy
Proven skill in IND preparation, managing CRO collaborations for toxicology, pharmacology and GMP manufacturing.
Scientific Due Diligence
Skilled in scientific due diligence for venture capital and pharma, with expertise in evaluating therapeutic pipelines, assessing data, and identifying key risks and opportunities.
Obtaining Non-Diluted Funding
Support the drafting and submission of non-dilutive funding applications, including government agency grants. Developing strategic proposals and aligning them with funding priorities.
Strategic Partnership Support
Provide expertise in scientific negotiations and data room preparation for pharmaceutical licensing deals, ensuring seamless collaboration and successful strategic partnerships.
“ Science knows no country, because knowledge belongs to humanity, and is the torch which illuminates the world. The great discoveries are those which benefit humanity. ”
– Louis Pasteur
About
Dr. Yu (Rebecca) Miao is a Stanford-trained biologist with over 20 years of experience driving innovation in biologics for oncology, autoimmune disorders, fibrosis, and rare diseases. She is the Chief Scientific Officer and the Co-founder of AKSO Biopharmaceutical Inc.. She has extensive expertise in therapeutic development, spanning biologic discovery, preclinical pharmacology, IND preparation, and managing CRO collaborations to ensure successful program advancement.
Dr. Miao is highly skilled in scientific negotiations for licensing and M&A, with a proven ability to articulate program value and prepare comprehensive data rooms for due diligence. Her strong track record in securing non-dilutive funding and aligning therapeutic programs with regulatory requirements underscores her ability to bridge science and strategy, enabling successful outcomes for biotech companies and investors.
